Comparison of Salivary Biormarkers Levels With Periodontal Clinical Parameters in Smokers and Non-Smokers With Different Periodontal Diseases
NCT ID: NCT06459037
Last Updated: 2025-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2024-05-10
2025-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary aim of this study is to evaluate the salivary levels of NRP-1 in systemically healthy individuals, including non-smokers with periodontal health, non-smokers with gingivitis, non-smokers with periodontitis, and smokers with periodontitis. Additionally, the study aims to compare the concentration of NRP-1 with C-reactive protein (CRP) levels across these groups to assess potential associations.
A secondary objective is to determine the impact of nicotine exposure by measuring salivary cotinine levels and exploring their relationship with the clinical and biochemical parameters assessed. The study will include a total of 80 participants, divided into four equal groups: 20 non-smokers with periodontal health, 20 patients with gingivitis, 20 non-smokers with periodontitis, and 20 smokers with periodontitis.
For all participants, comprehensive oral clinical parameters will be recorded, and unstimulated saliva samples will be collected. The concentrations of NRP-1, cotinine, and CRP in these samples will be determined using enzyme-linked immunosorbent assay (ELISA). Statistical analyses will then be conducted to evaluate differences in biomarker levels among the groups.
Significant variations in these biomarker levels may indicate that NRP-1 has potential utility as a diagnostic biomarker for periodontal diseases or as a marker to guide treatment strategies. Furthermore, the findings may contribute to a deeper understanding of the interplay between periodontitis and smoking.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Salivary Biomarker Levels of Individuals With Different Periodontal Diseases
NCT05774925
EVALUATION OF SALIVARY BİOMARKER LEVELS IN SMOKING AND NON-SMOKER INDIVIDUALS WITH DIFFERENT PERIODONTAL DISEASES
NCT06971770
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions
NCT06558136
Effect of Different Centrifuge Values on Saliva High Sensitive C-Reactive Protein (Hs-CRP) Levels in Individuals With Different Smoking Amounts
NCT06561971
Assessment of Salivary Biomarker Levels in Individuals With Various Periodontal Diseases
NCT07025291
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
"Periodontal diseases" encompass a range of chronic inflammatory conditions affecting the gingiva, alveolar bone, and periodontal ligaments. The process begins with gingivitis, characterized by sulcular pathogenic bacterial accumulation in the gingiva, and can progress to periodontitis, involving impaired host immune response and destruction of connective tissue attachment. Inflammation in affected tissues, degradation of connective tissue, and biochemical signaling in alveolar bone remodeling contribute to the observed clinical morbidity.
Plaque-induced gingivitis is a reversible inflammatory condition resulting from microbial biofilm accumulation on teeth and inadequate removal. It is characterized by gingival redness, swelling, and a tendency to bleed easily. With proper oral hygiene measures, it can resolve spontaneously within approximately one week. In susceptible individuals, gingivitis may progress to periodontitis. Periodontitis is characterized by connective tissue attachment loss and alveolar bone destruction following an inflammatory host response to periodontal pathogens. These destructions lead to the formation of pathological pockets, increased mobility, chewing dysfunction, patient discomfort, and ultimately tooth loss.
The role of specific bacterial species clusters in periodontal disease has been studied using various methods, from classical cultural techniques to molecular, genomic, and proteomic approaches. Certain bacterial species, such as Porphyromonas gingivalis, Tannerella forsythensis, and Treponema denticola, are commonly associated with periodontal disease. As periodontal disease progresses, the number of gram-negative and anaerobic bacteria in dental plaque increases. However, the presence of microbial biofilm alone may not be sufficient for disease development. The disease arises when the balance between microbial biofilm and host response is disrupted, leading to dysbiosis or an excessive immune response to microbial presence.
During periodontal infection, the release of bacterial leukotoxins, collagenases, fibrinolysins, and other proteases contributes to tissue destruction. Epithelial cells serve as a physical barrier against pathogens and initiate innate and adaptive immune responses. Dendritic Langerhans cells in the epithelium capture microbial antigens and transport them to lymphoid tissue for presentation to lymphocytes. This is followed by infiltration of neutrophils, granulocytes, and lymphocytes into the periodontal lesion. Neutrophils attempt to phagocytose and eliminate bacteria but may be insufficient against the size and chronic persistence of microbial biofilm. This intense chronic inflammatory response leads to alveolar bone resorption by osteoclasts and degradation of connective tissue fibers by matrix metalloproteinases, resulting in granulation tissue formation.
Neuropilins are transmembrane glycoproteins expressed in all vertebrates, with NRP-1 and NRP-2 identified as two distinct genes. NRP-1 is located on chromosome 10p12, while NRP-2 is on chromosome 2. Both genes contain 17 exons.Neuropilins lack intracellular tyrosine kinase domains but possess a large extracellular region and a short cytoplasmic tail of approximately 40 amino acids. Neuropilins regulate various functions, including homeostasis, angiogenesis, arteriogenesis, immune regulation, inflammation, cell migration during inflammation, communication with immune cells, cancer, and autoimmune diseases. NRP-1 enhances antigen presentation by facilitating interactions between dendritic cells and T cells. It is expressed in macrophages, dendritic cells, and especially T cells. NRP-1 has been shown to play a role in regulating vascular endothelial cell migration. Additionally, NRP-1 is involved in bone homeostasis and is expressed in osteoblasts and osteoclasts. NRP-1 serves as a receptor for Semaphorin-3A (SEMA3A), Vascular Endothelial Growth Factor-A (VEGF-A), VEGF-B, Placenta Growth Factor (PIGF), and microRNAs.
In periodontitis, there is an immune response against periodontal pathogens involving innate and adaptive immunity, which may include NRP-1 in the interaction between dendritic cells and T cells. An imbalance or dysregulation of this immune response leads to excessive tissue damage and irreversible destruction of dental support.
During acute inflammation, various cells, including macrophages, fibroblasts, and endothelial cells, release pro-inflammatory cytokines such as IL-6, TNF-α, IL-1β, and IL-22. These cytokines stimulate the liver to produce acute-phase proteins (APPs), including serum amyloid A (SAA) and C-reactive protein (CRP). CRP levels increase rapidly within 24 to 72 hours in response to inflammation or tissue damage and decrease after resolution of inflammation or infection. Elevated CRP levels have been linked to various inflammatory conditions, including periodontal diseases.
Saliva contains various components, including electrolytes, epithelial cells, antimicrobial peptides, and enzymes. Salivary analysis has shown potential diagnostic properties for identifying periodontal disease biomarkers. Saliva is considered an attractive diagnostic fluid for oral-related diseases due to its non-invasive collection, ease of obtaining, and presence of various biomarkers.
The study involves systemically healthy 80 participants, including 20 non-smoking individuals with healthy periodontium; 20 individuals with gingivitis; 20 individuals with periodontitis; and 20 smoking individuals with periodontitis. Saliva samples were collected from all participants to analyze the levels of NRP-1, cotinine, and CRP using ELISA (enzyme-linked immunosorbent assay) methods. Clinical periodontal parameters such as probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque index (PI) were also recorded.
Cotinine, the major metabolite of nicotine, is widely used as a biomarker of tobacco exposure due to its longer half-life (approximately 17 hours) compared to nicotine. Cotinine levels in saliva, serum, or urine can reflect both active and passive tobacco exposure, making it a reliable indicator for quantifying smoking status and intensity.
Smoking is a well-established modifiable risk factor for periodontal disease. It has been shown to alter host immune responses to microbial challenges in the oral cavity. Smoking affects various immune cell functions, such as reducing neutrophil and fibroblast activity, impairing immunoglobulin G (IgG) production, and decreasing the release of growth factors. On the other hand, it increases the expression of pro-inflammatory cytokines like PGE2, IL-1β, IL-6, IL-7, IL-8, IL-10, and IL-15, as well as the prevalence of periodontal pathogens.
Nicotine and its metabolites also affect the oral environment by increasing bacterial colonization on epithelial cells and reducing oxidative potential, promoting anaerobic conditions that favor pathogenic bacteria. These changes accelerate the progression of periodontal disease and complicate its management.
Interestingly, clinical signs of inflammation such as bleeding on probing may appear reduced in smokers due to the vasoconstrictive effects of nicotine, which limits gingival blood flow, edema, and visual signs of inflammation. Despite this, the underlying periodontal destruction may be more severe and progress unnoticed.
Although the relationship between salivary CRP levels and periodontal disease has been studied previously, there is a lack of data in the current literature regarding salivary NRP-1 levels in smoking individuals with periodontal disease. This study aims to fill that gap by examining how salivary levels of NRP-1, cotinine, and CRP vary in smokers versus non-smokers across different periodontal health statuses, and by determining whether NRP-1 can serve as a potential biomarker for periodontal disease progression influenced by smoking.
In conclusion, this study seeks to elucidate the diagnostic and prognostic significance of salivary NRP-1, cotinine, and CRP levels, particularly in the context of smoking and its effect on periodontal health. These findings may contribute to improved risk assessment and personalized approaches in periodontal diagnosis and treatment planning.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Periodontium
Individuals with less than 10% bleeding on probing, probing depth less than 4 mm, and no attachment loss, based on evaluation in 6 areas of each tooth.
Saliva obtaining
The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Gingivitis
Individuals who, in the evaluation made in 6 areas of each tooth, had bleeding on probing in more than 10% of the areas, had a probing depth of less than 4 mm and had no attachment loss.
Saliva obtaining
The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
non-smoker periodontitis
Individuals who have bleeding on probing in 30% or more of the area, who have a probing pocket depth of 5 mm or more in at least 2 non-adjacent teeth in each quadrant of the jaw, who have attachment loss of 4 mm or more, and who have coronal 1/3 or more (horizontal and/or vertical) bone loss on radiographs.
Saliva obtaining
The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
smoker periodontitis
Individuals who smoke at least 10 cigarettes per day, have bleeding on probing in 30% or more of the area, have a probing pocket depth of 5 mm or more in at least 2 non-adjacent teeth in each quadrant of the jaw, have attachment loss of 4 mm or more, and have coronal 1/3 or more (horizontal and/or vertical) bone loss on radiographs.
Saliva obtaining
The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saliva obtaining
The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 16 permanent teeth in the mouth
* For non-smoking groups: never smoked
* For the smoking group: smoking at least 10 cigarettes per day
* No continuously used medications
* No use of antibiotics, anti-inflammatory drugs, and systemic corticosteroids in the last 6 months
* Not pregnant or breastfeeding
* No periodontal treatment in the last 6 months
* For the Periodontitis group: based on the evaluation of 6 sites per tooth, ≥30% bleeding on probing, probing depth ≥5 mm and clinical attachment loss ≥4 mm in at least 2 non-adjacent teeth in a quadrant, and radiographic bone loss of coronal 1/3 or more (horizontal and/or vertical)
* For the Gingivitis group: based on the evaluation of 6 sites per tooth, ≥10% bleeding on probing, probing depth \<4 mm, and no clinical attachment loss
* For the Healthy group: based on the evaluation of 6 sites per tooth, \<10% bleeding on probing, probing depth \<4 mm, and no clinical attachment loss
Exclusion Criteria
* Regularly using a systemic medication
* During pregnancy or lactation
* Received periodontal treatment within the last 6 months.
* Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Izmir Katip Celebi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Şeyma Gündoğdu
Research Assistant at Periodontology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdullah Seçkin Ertuğrul, Prof. Dr.
Role: STUDY_DIRECTOR
Izmir Katip Çelebi University, Faculty of Dentistry, Department of Periodontology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Izmir Katip Çelebi University Department of Periodontology
Izmir, Çiğli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-TDU-DİŞF-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.